Thursday 16 October, 2025
Objectives: Vancomycin is commonly used to treat severe Gram-positive bacterial infections. Due to its highly variable PK and narrow therapeutic window,…
Read moreAbstracts
PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect
Thursday 16 October, 2025
Introduction: Chronic pain (CP) causes major discomfort and is highly prevalent [1]. Opioids are currently the most effective class of…
Read moreDose determination of morphine to investigate the analgesic effects of morphine and pregabalin in healthy subjects using a combined NONMEM model
Thursday 16 October, 2025
Introduction: Chronic pain (CP) is highly prevalent with 20.4%, and 7.4% of the adult US population suffering from chronic pain…
Read moreStepwise Covariate Modelling (SCM) versus Full Random Effects Modelling (FREM) for covariate modelling of correlated covariates exemplified with tigecycline and liver function markers
Thursday 16 October, 2025
Objectives: Covariate analysis in small datasets or in datasets with correlated covariates is challenging. This study compared the automated covariate…
Read moreBelimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis
Thursday 16 October, 2025
Introduction: The cytokine B-cell lymphocyte stimulating protein (BLyS) plays an important role in the production and differentiation of B cells…
Read morePharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics
Thursday 16 October, 2025
Background: Amiodarone (AM) is a class III antiarrhythmic drug in the treatment of life-threatening ventricular and supraventricular arrhythmias. Commercially available…
Read moreExternal validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa
Thursday 16 October, 2025
Background: Hidradenitis suppurativa (HS) is a chronic skin disease characterized by the presence of difficult-to-manage inflammatory nodules that can progress…
Read moreIndividualized dosing regimen optimization using a population pharmacokinetic-pharmacodynamic model for secukinumab in clinical practice psoriatic patients
Thursday 16 October, 2025
Introduction/Objectives: Psoriasis (Pso) is an inflammatory skin disease resulting from genetic, environmental, and immunological factors [1]. One of its main medical…
Read moreEstimation of a sensitive range of dose-adjusted FaSSIF solubility to predict the food effect on BCS II/IV drugs
Thursday 16 October, 2025
Introduction: The simultaneous administration of oral dosage forms with food can have a significant impact on drug pharmacokinetics [1]. Physiologically…
Read moreComputational analysis of cytokine release following bispecific T-cell engager therapy
Thursday 16 October, 2025
Introduction: Bispecific T cell Engager (BiTE®) molecules offer a promising treatment that uses the patient’s own immune system towards eliminating…
Read more